Forty Seven, a GV-backed immuno-oncology spinout from Stanford University, has filed for a $115m initial public offering on Nasdaq just eight months after closing a $75m series B.
US-based oncology therapy developer Forty Seven has filed for a $115m initial public offering on Nasdaq that would provide an exit to GV, the early-stage corporate venturing arm of diversified conglomerate Alphabet.
Spun out from Stanford University in 2015, Forty Seven is working on monoclonal antibodies, including its lead candidate, 5F9, which targets a protein called CD47. CD47 enables cancer cells to send signals telling the immune system not to attack.
The initial public offering follows the announcement of promising…
